Overview

Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens

Status:
Completed

Trial end date:
2016-08-16

Target enrollment:

Participant gender:

Summary

This phase II trial studies how well nintedanib works in treating patients with advanced non-small cell lung cancer who have failed up to two previous chemotherapy regimens. Nintedanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Phase:

Phase 2

Details

Lead Sponsor:

Roswell Park Cancer Institute

Collaborators:

Boehringer Ingelheim
National Cancer Institute (NCI)

Treatments:

Nintedanib